Providers bill — and earn — millions on oft-reported immunosuppressive drugs
Providers billing immunosuppressive drug claims saw some — but not much — resistance to the several hundred millions of claims they submitted in 2015 and 2016, according to an analysis of Medicare claims data from the two most recently available periods.
To read the full article, sign in and subscribe to the DecisionHealth Newsletters.